NCT06160167View on ClinicalTrials.gov

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

CompletedOBSERVATIONAL
Enrollment

4,204

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

IMiD treatment

Participants with MM treated with IMiDs

DRUG

No IMiD treatment

Participants with MM not treated with IMiDs

DRUG

Systemic therapy

Participants with MM treated with systemic therapy

Trial Locations (1)

10013

Flatiron Health Oncology Database, New York

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06160167 - Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | Biotech Hunter | Biotech Hunter